Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Taxus Cardium Pharmaceuticals Group Inc
CRXMCurrent price
0.0001 USD
0 USD (0.00%)
Last closed
0.0001 USD
Company
genebiotherapeutics.com
ISIN
US8767671048
Sector
Healthcare
Industry
Biotechnology
Exchange
PINK
Capitalization
6 493 USD
Yield for 12 month
0.00 %
1Y
3Y
5Y
10Y
15Y
CRXM
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California. Gene Biotherapeutics, Inc. is a subsidiary of Nostrum Pharmaceuticals, LLC. Address: 11230 Sorrento Valley Road, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
2 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
-1 816 USD
Current Quarter
–
Last Quarter
–
Key Figures CRXM
1 year
3 years
5 years
10 years
EBITDA
-1 260 365 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-261.9 %
PEG Ratio
–
Return On Equity TTM
–
Wall Street Target Price
2 USD
Revenue TTM
–
Book Value
-0.096 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.02 USD
Diluted Eps TTM
-0.02 USD
Most Recent Quarter
IV 2021
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CRXM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CRXM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:20
Payout Ratio
–
Last Split Date
18.07.2013
Dividend Date
–
Stock Valuation CRXM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
137.1275
Enterprise Value EBITDA
-1.4875
Price Book MRQ
3.3602
Financials CRXM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CRXM
For 52 weeks
0.0001 USD
0.0001 USD
50 Day MA
0.0001 USD
Shares Short Prior Month
448 453
200 Day MA
0.0001 USD
Short Ratio
1.03
Shares Short
150 251
Short Percent
1.78 %
BeatStart